전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
in vivo pētījumi liecina, ka lumirakoksibam ir zems potenciāls mijiedarboties ar cyp2c9 substrātiem.
in vivo studies suggest that lumiracoxib has low potential for interactions with cyp2c9 substrates.
마지막 업데이트: 2012-04-10
사용 빈도: 1
품질:
4 ’ - hidroksimetabolītam ir līdzīga iedarbība un cox- 2 selektivitāte kā lumirakoksibam.
the 4’ -hydroxy metabolite has similar potency and cox-2 selectivity to lumiracoxib.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
terapijas pārtraukšanas gadījumu skaits tūskas dēļ lumirakoksibam (43) un nspl (55) ievērojami neatšķīrās.
the number of discontinuations in target due to oedema was not significantly different between lumiracoxib (43) and nsaids (55).
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
diastoliskā asinsspiediena vidējā vērtība sākumpunktā bija - 0, 1 mm hg lumirakoksibam un +0, 5 mm hg nspl (p < 0, 0001).
for diastolic blood pressure, mean change from baseline were - 0.1 mmhg for lumiracoxib and +0.5 mmhg for nsaids (p < 0.0001).
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
katra 100 mg apvalkotā tablete satur 100 mg lumirakoksiba (lumiracoxib).
each 100 mg film-coated tablet contains 100 mg lumiracoxib.
마지막 업데이트: 2012-04-10
사용 빈도: 6
품질: